Acute Lymphoblastic Leukemia — NIH Grants & Funding

MONDO:0004967

Funding Landscape

Acute Lymphoblastic Leukemia has a robust NIH research funding landscape with 118 funded grants and $102.5M in total funding over the period.

118funded grants from NIH

Portfolio: $51.2MCumulative: $102.5M79 active39 completed134 PIs63 institutions

+49% YoY(FY2024 vs FY2025)

14 new grants started in the last 12 months.

By Research Theme

Basic Science

Translational

Clinical

Epi / Nat. History

Gene/Cell Therapy

Biomarker / Dx

Medical Device

1 additional grant classified as “Other” (multi-disciplinary, infrastructure, etc.).

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$14.2M

FY22

$15.6M

FY23

$27.4M

FY24

$40.9M

FY25

$4.4M

FY26

By Funding Mechanism

R01

R37

K08

R21

F30

F31

Basic Science(47)

Basic ScienceR01Active

Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia

Loh, Mignon et al.·SEATTLE CHILDREN'S HOSPITAL·SEATTLE, WA

$3,480,276 (FY2025)

NIH RePORTER

Basic ScienceZIACompleted

Cytokines and T Cell Development

DURUM, SCOTT·DIVISION OF BASIC SCIENCES - NCI

$1,532,973 (FY2025)

NIH RePORTER

Basic ScienceR01Active

Deciphering the underlying structure of the glucocorticoid gene regulatory network

Cheng, Yong et al.·ST. JUDE CHILDREN'S RESEARCH HOSPITAL·MEMPHIS, TN

$814,368 (FY2025)

NIH RePORTER

Basic ScienceR01Active

Cytomegalovirus as an etiologic and clinico-pathogenic factor in childhood acute lymphoblastic leukemia

Ma, Xiaomei et al.·UNIVERSITY OF SOUTHERN CALIFORNIA·Los Angeles, CA

$676,777 (FY2025)

NIH RePORTER

Basic ScienceR01Active

Variant to Function Mapping of B-ALL Risk Loci

De Smith, Adam et al.·BOSTON CHILDREN'S HOSPITAL·BOSTON, MA

$669,524 (FY2025)

NIH RePORTER

Basic ScienceR01Active

A Molecular Approach to Dissecting MEK-Mediated Phosphorylation in Pediatric Leukemia

Lacorazza, Daniel et al.·NORTHWESTERN UNIVERSITY·Chicago, IL

$652,805 (FY2025)

NIH RePORTER

Basic ScienceR01Active

Overcoming resistance to menin patient mutations in leukemia

Grembecka, Jolanta·UNIVERSITY OF MICHIGAN AT ANN ARBOR·ANN ARBOR, MI

$640,135 (FY2025)

NIH RePORTER

Basic ScienceR01Active

New control of oncogene activation in T-cell leukemia

Liang, Chengyu·WISTAR INSTITUTE·PHILADELPHIA, PA

$525,427 (FY2025)

NIH RePORTER

Basic ScienceR37Active

The Role and Function of a Novel Signature Gene in BCR::ABL1 (Ph) B-cell Acute Lymphoblastic Leukemia

Gu, Zhaohui·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$517,090 (FY2025)

NIH RePORTER

Basic ScienceR01Active

Exploring microRNA degradation in T-cell acute lymphoblastic leukemia

Licht, Jonathan et al.·UNIVERSITY OF FLORIDA·GAINESVILLE, FL

$503,845 (FY2025)

NIH RePORTER

Translational(24)

TranslationalR44Active

Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia

Breitfeld, Philip et al.·FANNIN PARTNERS, LLC·HOUSTON, TX

$999,997 (FY2025)

NIH RePORTER

TranslationalR44Active

Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies

Hein, Sarah et al.·MARCH BIOSCIENCES INC·HOUSTON, TX

$986,080 (FY2025)

NIH RePORTER

TranslationalR01Active

Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias

Jin, Jian et al.·ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI·NEW YORK, NY

$654,354 (FY2025)

NIH RePORTER

TranslationalR01Active

Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)

CALABRETTA, BRUNO et al.·THOMAS JEFFERSON UNIVERSITY·PHILADELPHIA, PA

$631,337 (FY2025)

NIH RePORTER

TranslationalR01Active

Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner

Jin, Jian et al.·DUKE UNIVERSITY·DURHAM, NC

$576,864 (FY2026)

NIH RePORTER

TranslationalR37Active

Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines

Kenderian, Saad·MAYO CLINIC ROCHESTER·ROCHESTER, MN

$554,542 (FY2026)

NIH RePORTER

TranslationalR01Active

Novel targeted therapy to reduce health disparities in pediatric leukemia

Dovat, Sinisa·PENNSYLVANIA STATE UNIV HERSHEY MED CTR·HERSHEY, PA

$541,022 (FY2025)

NIH RePORTER

TranslationalR01Active

Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias

Jin, Jian et al.·ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI·NEW YORK, NY

$514,092 (FY2025)

NIH RePORTER

TranslationalR01Active

Dissecting the Functional Role of PAX5 Mutations in B-cell Acute Lymphoblastic Leukemia

Gu, Zhaohui·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$483,110 (FY2025)

NIH RePORTER

TranslationalR01Active

Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia

Song, Yongcheng·BAYLOR COLLEGE OF MEDICINE·HOUSTON, TX

$437,571 (FY2025)

NIH RePORTER

Clinical(15)

ClinicalR01Active

Improving risk allocation and developing novel therapies for children with T-ALL and T-LL

Horton, Terzah et al.·CHILDREN'S HOSP OF PHILADELPHIA·PHILADELPHIA, PA

$663,617 (FY2026)

NIH RePORTER

ClinicalR37Active

The AYA Oncology Self-Care Movement (#AYAOSM): An Influencer-Driven Social Media Intervention for Oral Chemotherapy Adherence

Psihogios, Alexandra·LURIE CHILDREN'S HOSPITAL OF CHICAGO·CHICAGO, IL

$651,859 (FY2025)

NIH RePORTER

ClinicalR01Active

Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia

Davis, Kara·STANFORD UNIVERSITY·STANFORD, CA

$570,059 (FY2025)

NIH RePORTER

ClinicalR37Active

Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia

van der Plas, Ellen·ARKANSAS CHILDREN'S HOSPITAL RES INST·LITTLE ROCK, AR

$559,503 (FY2025)

NIH RePORTER

ClinicalR01Active

Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescentsand Young Adults with Acute Lymphoblastic Leukemia

Wolfson, Julie·UNIVERSITY OF ALABAMA AT BIRMINGHAM·BIRMINGHAM, AL

$540,972 (FY2025)

NIH RePORTER

ClinicalR01Active

Preventing Fatal Infections in Children with Down Syndrome During Treatment for Acute Lymphoblastic Leukemia

Rabin, Karen et al.·COLUMBIA UNIVERSITY HEALTH SCIENCES·NEW YORK, NY

$533,887 (FY2025)

NIH RePORTER

ClinicalR01Active

Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL

Carlesso, Nadia·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$467,705 (FY2026)

NIH RePORTER

ClinicalU01Active

NCI Pediatric In Vivo Testing Program - Leukemia

Lock, Richard·UNIVERSITY OF NEW SOUTH WALES·SYDNEY

$454,977 (FY2025)

NIH RePORTER

ClinicalK08Active

A Healthy Weight Intervention for Family Stress during the Early Phases of ALL Treatment: NOURISH-ALL

Bates, Carolyn·UNIVERSITY OF KANSAS MEDICAL CENTER·KANSAS CITY, KS

$207,099 (FY2025)

NIH RePORTER

ClinicalR50Active

Pediatric acute lymphoblastic leukemia: Improving outcomes through incorporation of novel targeted therapies into treatment for relapsed and newly diagnosed disease

O'Brien, Maureen·UNIVERSITY OF COLORADO DENVER·Aurora, CO

$172,013 (FY2025)

NIH RePORTER

Epi / Nat. History(14)

Epi / Nat. HistoryR01Active

Prevalence and persistence of the ETV6/RUNX1 pre-leukemic clone

Marcotte, Erin et al.·UNIVERSITY OF MINNESOTA·MINNEAPOLIS, MN

$2,254,636 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR01Active

A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia

Brown, Austin et al.·BAYLOR COLLEGE OF MEDICINE·HOUSTON, TX

$608,609 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR01Active

Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos

De Smith, Adam·UNIVERSITY OF SOUTHERN CALIFORNIA·Los Angeles, CA

$601,736 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR37Active

Defining the Mechanism of Genome Rearrangements in Ph-Like ALL to Determine Predictive Markers in High-Risk Hispanic Populations

Pannunzio, Nicholas·UNIVERSITY OF CALIFORNIA-IRVINE·IRVINE, CA

$366,163 (FY2026)

NIH RePORTER

Epi / Nat. HistoryR37Active

Targeting obesity to improve survival from childhood acute lymphoblastic leukemia

Orgel, Etan·CHILDREN'S HOSPITAL OF LOS ANGELES·LOS ANGELES, CA

$312,066 (FY2025)

NIH RePORTER

Epi / Nat. HistoryR01Active

Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos

De Smith, Adam·UNIVERSITY OF SOUTHERN CALIFORNIA·Los Angeles, CA

$132,240 (FY2022)

NIH RePORTER

Epi / Nat. HistoryR01Active

Genomics of childhood acute lymphoblastic leukemia in the Childhood Cancer and Leukemia International Consortium

Basu, Saonli et al.·UNIVERSITY OF MINNESOTA·MINNEAPOLIS, MN

$101,629 (FY2025)

NIH RePORTER

Epi / Nat. HistoryF31Active

Exploring the Impact of Genetic Ancestry on Acute Lymphoblastic Leukemia Risk in Latino Populations

Langie, Jalen·UNIVERSITY OF SOUTHERN CALIFORNIA·Los Angeles, CA

$49,538 (FY2026)

NIH RePORTER

Epi / Nat. HistoryR01Active

An Integrative Approach to Evaluate Neurocognitive Disparities in Latinos Undergoing Treatment for Childhood Leukemia.

Brown, Austin et al.·BAYLOR COLLEGE OF MEDICINE·HOUSTON, TX

$1 (FY2025)

NIH RePORTER

Epi / Nat. HistoryP20Completed

Improving Outcome Disparities for Latino Children and Adolescents with Acute Lymphoblastic Leukemia

Lupo, Philip et al.·BAYLOR COLLEGE OF MEDICINE·HOUSTON, TX

$1,027,258 (FY2023)

NIH RePORTER

Gene/Cell Therapy(10)

Gene/Cell TherapyR01Active

BAFF-R CAR T cell therapy for ALL

ALDOSS, IBRAHIM et al.·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$677,623 (FY2025)

NIH RePORTER

Gene/Cell TherapyR01Active

Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies

Alinari, Lapo et al.·OHIO STATE UNIVERSITY·Columbus, OH

$609,273 (FY2025)

NIH RePORTER

Gene/Cell TherapyU01Active

Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia

Yang, Jun et al.·ST. JUDE CHILDREN'S RESEARCH HOSPITAL·MEMPHIS, TN

$528,622 (FY2025)

NIH RePORTER

Gene/Cell TherapyR37Active

Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-cell Acute Lymphoblastic Leukemia

Witkowski, Matthew·UNIVERSITY OF COLORADO DENVER·Aurora, CO

$417,865 (FY2026)

NIH RePORTER

Gene/Cell TherapyK08Active

Improving CAR T-cell therapy for Pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL)

Talleur, Aimee·ST. JUDE CHILDREN'S RESEARCH HOSPITAL·MEMPHIS, TN

$289,458 (FY2025)

NIH RePORTER

Gene/Cell TherapyK08Active

Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL

Niswander, Lisa·ROSWELL PARK CANCER INSTITUTE CORP·BUFFALO, NY

$196,110 (FY2025)

NIH RePORTER

Gene/Cell TherapyK08Active

Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy

Myers, Regina·CHILDREN'S HOSP OF PHILADELPHIA·PHILADELPHIA, PA

$180,885 (FY2025)

NIH RePORTER

Gene/Cell TherapyF30Active

Activating Low-Affinity T Cells to Prevent Relapse in Acute Lymphoblastic Leukemia

Luo, Qianyun·UNIVERSITY OF MINNESOTA·MINNEAPOLIS, MN

$54,538 (FY2025)

NIH RePORTER

Gene/Cell TherapyK08Completed

Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia

Raikar, Sunil·EMORY UNIVERSITY·ATLANTA, GA

$224,496 (FY2024)

NIH RePORTER

Gene/Cell TherapyF31Completed

Investigating the Role of Cdc73 in T-cell Acute Lymphoblastic Leukemia (T-ALL)

Melnick, Ashley·UNIVERSITY OF MICHIGAN AT ANN ARBOR·ANN ARBOR, MI

$14,329 (FY2023)

NIH RePORTER

Biomarker / Dx(4)

Biomarker / DxR01Active

Brain-Imaging Markers of Neurotoxicity and Long-Term Outcomes after CAR-T Cell Therapy

Bansal, Ravi et al.·CHILDREN'S HOSPITAL OF LOS ANGELES·LOS ANGELES, CA

$704,305 (FY2025)

NIH RePORTER

Biomarker / DxR01Active

Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia

Teachey, David et al.·ST. JUDE CHILDREN'S RESEARCH HOSPITAL·MEMPHIS, TN

$599,172 (FY2025)

NIH RePORTER

Biomarker / DxR01Completed

Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcome

Savic, Daniel·ST. JUDE CHILDREN'S RESEARCH HOSPITAL·MEMPHIS, TN

$488,482 (FY2023)

NIH RePORTER

Biomarker / DxR33Completed

Increased Sensitivity of Minimal Residual Disease Monitoring using Peripheral Blood in Pediatric Patients with Acute Lymphoblastic Leukemia

August, Keith et al.·UNIVERSITY OF KANSAS LAWRENCE·LAWRENCE, KS

$245,275 (FY2022)

NIH RePORTER

Medical Device(3)

Medical DeviceR44Active

Reduced Traumatic Lumbar Puncture Rates in Pediatric Oncology Patients Through Development of an AI-Assisted, Ultrasound-Based Interventional Guidance Platform

Mauldin, Frank·RIVANNA MEDICAL, INC.·CHARLOTTESVILLE, VA

$1,073,736 (FY2025)

NIH RePORTER

Medical DeviceN43Completed

Ultrasound-based Diagnosis and Monitoring of Neutropenic Enterocolitis in Children with Acute Lymphoblastic Leukemia

Kumar, Viksit·NOVATEUR RESEARCH SOLUTIONS, LLC·Ashburn, VA

$354,985 (FY2024)

NIH RePORTER

Medical DeviceR41Completed

Feasibility of a mobile application for sleep and circadian rhythms in pediatric patients with acute lymphoblastic leukemia and their caregivers

Walch, Olivia·ARCASCOPE, INC·CHANTILLY, VA

$273,613 (FY2023)

NIH RePORTER

Other(1)

OtherR21Active

Mitochondrial Dysfunction underlies treatment related hepatotoxicity in Hispanics with acute lymphoblastic leukemia

Alachkar, Houda·UNIVERSITY OF SOUTHERN CALIFORNIA·Los Angeles, CA

$442,404 (FY2023)

NIH RePORTER

Adjacent Research(38 grants)

These grants mention Acute Lymphoblastic Leukemia as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(38)

OtherP01Active

Fusion oncoprotein condensates in pediatric cancers

KRIWACKI, RICHARD et al.·ST. JUDE CHILDREN'S RESEARCH HOSPITAL·MEMPHIS, TN

$3,032,826 (FY2025)

NIH RePORTER

OtherP01Active

Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19

JUNE, CARL·UNIVERSITY OF PENNSYLVANIA·PHILADELPHIA, PA

$2,863,199 (FY2025)

NIH RePORTER

OtherU54Active

Reducing Disparities in Acute Leukemia (REDIAL) Consortium

Gramatges, Maria et al.·BAYLOR COLLEGE OF MEDICINE·HOUSTON, TX

$2,494,110 (FY2025)

NIH RePORTER

OtherP01Active

The impact of changes in chromatin architecture on cancer phenotypes and tumor progression

Skok, Jane·NEW YORK UNIVERSITY SCHOOL OF MEDICINE·NEW YORK, NY

$2,304,725 (FY2025)

NIH RePORTER

OtherP50Active

Specialized Program of Research Excellence (SPORE) in Leukemia

Link, Daniel·WASHINGTON UNIVERSITY·SAINT LOUIS, MO

$2,183,320 (FY2025)

NIH RePORTER

OtherP01Active

Off-the-Shelf Immune Effector Cells for Hematological Malignancies

Wagner, John·UNIVERSITY OF MINNESOTA·MINNEAPOLIS, MN

$2,080,518 (FY2025)

NIH RePORTER

OtherP01Active

Development of Novel Therapeutic Strategies in Human Leukemias

ARMSTRONG, SCOTT et al.·DANA-FARBER CANCER INST·BOSTON, MA

$2,052,164 (FY2025)

NIH RePORTER

OtherZIACompleted

Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies

Shah, Nirali·DIVISION OF BASIC SCIENCES - NCI

$834,260 (FY2025)

NIH RePORTER

OtherZIACompleted

Comprehensive Interrogation of Toxicity Profiles Associated with Novel CAR T-cell Constructs

Shah, Nirali·DIVISION OF BASIC SCIENCES - NCI

$834,260 (FY2025)

NIH RePORTER

OtherR01Active

Building the foundations of commensal vaccines

FISCHBACH, MICHAEL·STANFORD UNIVERSITY·STANFORD, CA

$730,870 (FY2025)

NIH RePORTER

Top Funded Institutions

ST. JUDE CHILDREN'S RESEARCH HOSPITAL$4.1M

TN10 grantsTalleur, Aimee, Ma, Xiaotu +3

UNIVERSITY OF MINNESOTA$4.0M

MN8 grantsLuo, Qianyun, Basu, Saonli +3

BAYLOR COLLEGE OF MEDICINE$3.5M

TX8 grantsBernhardt, Melanie, Lacorazza, Daniel +3

SEATTLE CHILDREN'S HOSPITAL$3.5M

WA1 grantLoh, Mignon, TASIAN, SARAH +1

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE$2.9M

CA6 grantsGu, Zhaohui, Parekh, Chintan +3

UNIVERSITY OF SOUTHERN CALIFORNIA$2.0M

CA6 grantsLangie, Jalen, De Smith, Adam +3

UNIVERSITY OF MICHIGAN AT ANN ARBOR$1.7M

MI5 grantsLin, Karena, RYAN, RUSSELL +3

DIVISION OF BASIC SCIENCES - NCI$1.5M

1 grantDURUM, SCOTT

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI$1.2M

NY2 grantsJin, Jian, Wang, G Greg +1

THOMAS JEFFERSON UNIVERSITY$1.1M

PA2 grantsLi, Jianping, CALABRETTA, BRUNO +1

Top Principal Investigators

Yang, Jun$4.6M

ST. JUDE CHILDREN'S RESEARCH HOSPITAL·3 grants

Basic ScienceBiomarker / DxGene/Cell Therapy

Loh, Mignon$3.5M

SEATTLE CHILDREN'S HOSPITAL·1 grant

Basic Science

TASIAN, SARAH$3.5M

SEATTLE CHILDREN'S HOSPITAL·1 grant

Basic Science

Marcotte, Erin$2.3M

UNIVERSITY OF MINNESOTA·1 grant

Epi / Nat. History

NELSON, HEATHER$2.3M

UNIVERSITY OF MINNESOTA·1 grant

Epi / Nat. History

Rabin, Karen$2.2M

BAYLOR COLLEGE OF MEDICINE·3 grants

ClinicalEpi / Nat. History

Jin, Jian$1.7M

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI·3 grants

Translational

Lupo, Philip$1.7M

BAYLOR COLLEGE OF MEDICINE·2 grants

Epi / Nat. History

DURUM, SCOTT$1.5M

DIVISION OF BASIC SCIENCES - NCI·1 grant

Basic Science

De Smith, Adam$1.5M

UNIVERSITY OF SOUTHERN CALIFORNIA·4 grants

Epi / Nat. HistoryBasic Science

Track funding opportunities for Acute Lymphoblastic Leukemia.

Follow this disease to be notified about new NIH grants and funding changes.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.